OncLive SOSS

Recent Advances in the Treatment of Prostate Cancer - Episode 17

Results of the VISION Trial and Real-World Use of 177Lu-PSMA-617 in mCRPC

May 25, 2022

Alicia Morgans, MD, MPH, Matthew Smith, MD, PhD, Sandy Srinivas, MD, Stanford University Medical Center, Scott T. Tagawa, MD, MS, Evan Y. Yu, MD

Reflections on results of the VISION trial, which utilized 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: Overview of Improvements in Prostate Cancer Management

EP. 2: Optimizing Use of PSMA PET Imaging and PSADT in Prostate Cancer

EP. 3: Evolving Treatment Landscape of Nonmetastatic CRPC

EP. 4: Factors in Selecting Novel AR-Targeted Therapy for Nonmetastatic CRPC

EP. 5: Nonmetastatic Castration-Resistant Prostate Cancer: Quality of Life Measures

EP. 6: Monitoring Strategies in Nonmetastatic CRPC

EP. 7: Overview of Treatment for Metastatic HSPC

EP. 8: Role of Micronized Abiraterone in Metastatic HSPC

EP. 9: Selecting Optimal Therapy for mHSPC: Design of the ARASENS Trial

EP. 10: Interpreting Data From the ARASENS Trial in Metastatic HSPC

EP. 11: Overview of Therapy for mCRPC: PARP Inhibitors

EP. 12: DNA Alterations and Selection of PARP Inhibitors in mCRPC

EP. 13: Metastatic CRPC: Utility of Imaging as a Biomarker

EP. 14: Selecting Among Novel Imaging Options in Metastatic CRPC

EP. 15: Role of 177Lu-PSMA-617 in mCRPC and Bone Metastases

EP. 16: Addressing Bone and Visceral Metastases in Metastatic CRPC

EP. 17: Results of the VISION Trial and Real-World Use of 177Lu-PSMA-617 in mCRPC

EP. 18: Prostate Cancer Management: Future Directions in Care

x